Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Simón bacteriophage
- Development stage
- Preclinical
- Lead developer
- Alfred Health
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Intravenous
01
Overview
Simón bacteriophage (øSimón) is an environmental siphovirus bacteriophage developed by Monash University and Alfred Health for the treatment of multidrug-resistant *Bordetella bronchialis* infections. It was isolated from wastewater in Melbourne, Australia, and characterized as a siphovirus with a 60,921 bp genome. øSimón targets *B. bronchialis* by binding to the outer membrane cobalamin transporter BtuB. It has been evaluated under compassionate use in a patient with cystic fibrosis suffering from recurrent, life-threatening *B. bronchialis* bacteremia and pneumonia. However, the therapy failed due to pre-existing neutralizing antibodies that cross-reacted with the therapeutic phage, driven by the patient's immune response to induced prophages from the causative bacteria, as well as bacterial heteroresistance.
- Other names
- phiSimónøSimón
02
Targets
Cer (Ceramide)
Beyond the preview
Go deeper on Simón bacteriophage.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Simón bacteriophage.